# 2026-19700: FDA Debates New Atropine Eye Drops Approval

2026-19700, Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01%, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-09-25, effective 2026-10-30 (as of 2026-10-02).

- Canonical: https://policyrisk.com/federal-register/2026-19700
- As of: 2026-10-02
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-19700
- Title: Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01%
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 60969
- Published: 2026-09-25
- Effective: 2026-10-30
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-10-02

## In one line

FDA Debates New Atropine Eye Drops Approval

## Summary

The FDA is holding a public meeting on October 30, 2026, to discuss a new eye drop medicine called Atropine Sulfate Ophthalmic Solution, 0.01%. This meeting lets people share their thoughts before the FDA decides if the drug should be approved. Anyone interested, especially patients and eye care providers, can join online or in person and send comments by October 29, 2026.

## Abstract

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2026-19700 on federalregister.gov](https://www.federalregister.gov/documents/2026/09/25/2026-19700/dermatologic-and-ophthalmic-drugs-advisory-committee-notice-of-meeting-establishment-of-a-public)
- [2026-19700 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-09-25/pdf/2026-19700.pdf)

## Related
- [Previous: 2026-19699, Foreign-Trade Zone (FTZ) 57, Notification of Proposed Production Activity; Eli…](https://policyrisk.com/federal-register/2026-19699)
- [Next: 2026-19701, Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holdin…](https://policyrisk.com/federal-register/2026-19701)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-19700 (as of 2026-10-02).